Immunotherapy revolutionizing buccal carcinoma treatment: Harnessing immune checkpoint inhibitors to overcome immune evasion mechanisms

Immunotherapy revolutionizing buccal carcinoma treatment: Harnessing immune checkpoint inhibitors to overcome immune evasion mechanisms

Saved in:

Bibliographic Details
Main Author:	S. Menaka
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Oral Oncology Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772906024003467
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunotherapeutic Potential of Lactobacillus Species as Immune Checkpoint Inhibitors in Cancer Immunotherapy
by: Renukadevi J, et al.
Published: (2025-01-01)

Overcoming immune evasion with innovative multi-target approaches for glioblastoma
by: Hai Su, et al.
Published: (2025-01-01)

Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion
by: Peng Huang, et al.
Published: (2025-01-01)

Tumor microenvironment immunotherapy: Transforming cancer treatment and immune checkpoint inhibitors - Future directions and challenges
by: Jeeva Jothi Kumaravel, et al.
Published: (2024-06-01)

Resistance mechanisms to immune checkpoint inhibitors: updated insights
by: Besan H. Alsaafeen, et al.
Published: (2025-01-01)

Immunotherapy in oral cancer treatment: Harnessing the immune system to combat oral squamous cell carcinoma
by: Santosh R. Patil
Published: (2024-06-01)

Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)

Subacute parkinsonism induced by immune checkpoint inhibitors
by: Lénia Silva, et al.
Published: (2024-12-01)

RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
by: Sara Egea‐Rodriguez, et al.
Published: (2025-01-01)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
by: Ryan S. Chiang, et al.
Published: (2020-01-01)

Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)
by: Iadalin Ryntathiang, et al.
Published: (2024-09-01)

Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma
by: Julian L. Goggi, et al.
Published: (2021-01-01)

Overcoming immunosuppression in cancer: how ketogenic diets boost immune checkpoint blockade
by: Victoria E. Stefan, et al.
Published: (2024-11-01)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
by: Yan Xiao, et al.
Published: (2020-01-01)

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
by: Douglas B Johnson, et al.
Published: (2024-07-01)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
by: Maansi Joshi, et al.
Published: (2020-01-01)

Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors
by: Francesca De Felice, et al.
Published: (2015-01-01)

Multiple stellate keratitis during immune checkpoint inhibitor therapy
by: Isana Nakajima, et al.
Published: (2025-03-01)

Virus Immune Evasion: New Mechanism and Implications in Disease Outcome
by: Rika Draenert, et al.
Published: (2012-01-01)

Immune Evasion Strategies of Trypanosoma cruzi
by: Ana Flávia Nardy, et al.
Published: (2015-01-01)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
by: Ernest Choy, et al.
Published: (2023-01-01)

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
by: JinSong Li, et al.
Published: (2025-02-01)

Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells
by: Luciana Melo Garcia, et al.
Published: (2025-01-01)

Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors
by: Yuhui Yang, et al.
Published: (2025-02-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Efficacy and safety of immune checkpoint inhibitors in patients with advanced intrahepatic cholangiocarcinoma
by: Ziting Peng, et al.
Published: (2025-02-01)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
by: Sandra M Herrmann, et al.
Published: (2023-01-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors
by: Xinyue Han, et al.
Published: (2025-01-01)

Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer
by: Pietro Parcesepe, et al.
Published: (2016-01-01)

Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
by: Coraline Radermecker, et al.
Published: (2021-03-01)

A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy
by: Manqing Peng, et al.
Published: (2024-12-01)

Trogocytosis-mediated immune evasion in the tumor microenvironment
by: Jeonghyun Kim, et al.
Published: (2025-01-01)

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
by: Maki Todo, et al.
Published: (2025-02-01)

Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics
by: B.E. Nelson, et al.
Published: (2025-03-01)

Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation
by: Chang Liu, et al.
Published: (2021-01-01)

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors
by: Zixi Wu, et al.
Published: (2025-12-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations
by: Andrew H. Coles
Published: (2025-03-01)